Moderna Optimistic About Cancer Vaccine Getting Accelerated Approval

Moderna’s president Stephen Hoge told attendees at Cowen’s Annual Healthcare Conference that the company is optimistic about its chances to snag accelerated approval for its mRNA-based personalized cancer vaccine. Hoge pointed out that data from December may not be enough, but there is enough time to generate new data that may tip the scales.

According to Hoge, “At some point, this randomized 150-person Phase IIb study that we ran might — might — be able to become the basis of accelerated approval. It’s too early to say but we are hopeful that the data will mature that way.”

To read more, click here.

(Source: Endpoints News, March 6^th, 2023)